Earnings call transcript: Cellectar Biosciences Q4 2025 reveals strategic cost control

NodeGuardian · 2026-03-14T12:28:20+00:00

Cellectar Biosciences reported a 51.1% decrease in net losses for Q4 2025 and extended its cash runway to Q3 2026, prompting a premarket stock rise. The company is advancing Iopofosine I-131 for Waldenstrom’s macroglobulinemia and enhancing its radiopharmaceutical programs and infrastructure.

NodeGuardian

2026-03-14 12:28:20

Abstract generation in progress

Cellectar Biosciences announced its Q4 2025 earnings, highlighting a significant 51.1% reduction in net losses and an extended cash runway into Q3 2026, leading to a 4.1% premarket stock increase. The company is advancing its lead asset, Iopofosine I-131, towards regulatory submissions in Europe and the U.S. for Waldenstrom’s macroglobulinemia, with strong clinical data supporting its potential in an earlier line of therapy. Additionally, Cellectar is progressing other radiopharmaceutical programs and has expanded its intellectual property and supply chain infrastructure.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.